TempraMed Reports over 275 Clinicians Recommending VIVI Cap to Patients on Leading FrontrowMD Platform Across the United States

Partnership results in over 275 physicians recommending VIVI Cap to patients, strengthening clinical validation and driving scalable patient education and acquisition

Vancouver, British Columbia–(Newsfile Corp. – February 26, 2026) – TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) (“TempraMed” or the “Company”), a medical-technology innovator transforming how temperature-sensitive medications are stored and managed, is pleased to announce that more than 275 physicians across the United States have recommended and included VIVI Cap in the offers available to their patients across FrontrowMD, a leading physician engagement and education platform.

The Company’s partnership with FrontrowMD and the subsequent positive reception from physicians across the United States represents another significant milestone in TempraMed’s commercialization strategy, validating strong physician demand for practical, real-world solutions that protect temperature-sensitive medications beyond the pharmacy and clinic setting.

Partnership Highlights

• FrontrowMD, is a trusted platform enabling physician-led product education and patient recommendation
• Over 275 physicians are sharing VIVI Cap to patients across multiple therapeutic areas and growing
• The physician-driven adoption model strengthens trust, compliance, and patient engagement
• Scalable channel supports sustained B2C demand generation through clinical endorsement
• TempraMed’s positioning as a standard-of-care adjunct for temperature-sensitive medications is reinforced

“Physician recommendations are the most powerful drivers of patient behavior in healthcare,” said Ron Nagar, CEO of TempraMed. “This partnership with FrontrowMD validates that clinicians recognize temperature exposure as a real and under-addressed risk to medication effectiveness. For TempraMed, this is not just awareness it is clinical endorsement translating directly into patient adoption at scale.”

“What stands out to me about the VIVI Cap is that it can provide continuous protection without requiring advance planning” said Dr. Knotresha Stewart of River Valley Healthcare Associates. “The cap is made from aerospace-derived technology to protect insulin during normal changes in temperature. For example, many patients move during the day between air-conditioned buildings and areas with direct sunlight. When this occurs, even for short periods, it can damage the integrity of the medication.”

Unlike traditional consumer marketing, this model positions TempraMed within the clinical workflow, reinforcing the company’s strategy to build adoption through professional trust, education, and real-world relevance and evidence.

The FrontrowMD partnership, initially launched in December 2025, complements TempraMed’s broader commercialization efforts across pharmacy, direct-to-consumer, and enterprise channels, while strengthening its credibility among healthcare professionals nationwide.

About TempraMed Technologies Ltd.

TempraMed Technologies Ltd. Is a global medical device company with a portfolio of innovative, temperature-controlled medication storage solutions. Founded with the mission to safeguard the effectiveness of life-saving medications, TempraMed develops patented, FDA-registered, thermal insulation devices that work 24/7 without batteries or external power. With a product line already in market including VIVI Cap, VIVI Cap Smart, VIVI Epi, and VIVI Med, TempraMed enables patients and healthcare providers to confidently manage temperature-sensitive medications anywhere, anytime. With operations in North America, Europe, and Asia, TempraMed will continue to expand globally offering a solution for medication protection and adherence.

About FrontrowMD

FrontrowMD is a physician engagement platform that enables healthcare professionals to discover, evaluate, and recommend innovative healthcare solutions to their patients. By combining education, trusted clinical voices, and compliant engagement tools, FrontrowMD helps bridge the gap between emerging medical technologies and real-world patient care. For more information visit: https://www.frontrowmd.com/

For further information, please contact:

Investors interested in learning more about TempraMed are encouraged to contact the Company at:

Cautionary Statements

This press release contains “forward-looking information” and “forward-looking statements” within the meaning of applicable Canadian securities legislation (collectively, “forward-looking statements”). Forward-looking statements may be identified by words such as “anticipate,” “believe,” “expect,” “intend,” “may,” “plan,” “will,” “should,” “strategy,” “future,” “potential,” and similar expressions, or statements about events or conditions that may occur in the future.

Forward-looking statements in this press release include, without limitation, statements regarding: the anticipated benefits of the partnership with FrontrowMD, including expected physician adoption rates and patient acquisition; the Company’s ability to scale the physician-driven recommendation model; the expected impact of clinical endorsement on consumer demand and revenue growth; TempraMed’s commercialization strategy across pharmacy, direct-to-consumer, and enterprise channels; and the Company’s ability to position its products as a standard-of-care adjunct for temperature-sensitive medications.

Forward-looking statements are based on the opinions, expectations, and assumptions of management as of the date of this press release, including but not limited to: that the FrontrowMD partnership will continue on its current terms and expand physician participation; that physician recommendations will translate into meaningful patient adoption and product sales; that the Company will have sufficient financial resources to support its commercialization initiatives; that market demand for temperature-controlled medication storage solutions will continue; and that the Company’s multi-channel commercialization strategy will perform as anticipated.

Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those expressed or implied, including but not limited to: the Company’s dependence on third-party partnerships for distribution and physician engagement; the risk that physician recommendations may not translate into anticipated sales volumes; the Company’s ability to secure additional financing; changes in regulatory requirements; competitive developments in temperature-controlled medication storage; general economic, market, and business conditions; and other risks described in the Company’s public filings available on SEDAR+ at www.sedarplus.ca.The forward-looking statements contained in this press release are made as of the date hereof. Except as required by applicable securities laws, the Company does not undertake any obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events, or otherwise.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/285359